Results 151 to 160 of about 26,226 (199)

Bleeding and thrombotic events in patients with heparin-induced thrombocytopenia: a two-decade single-center experience in Thailand. [PDF]

Thromb J
Chantarawichian Y, Suwanawiboon B, Ruchutrakool T, Chinthammitr Y, Rungjirajittranon T.   +4 more
europepmc   +1 more source

Heparin-Induced Thrombocytopenia Following Tinzaparin Administration: A Case Report. [PDF]

Cureus
Khallaf L, Katarki P, Ahmad N, Govindagowda T.   +3 more
europepmc   +1 more source

Preferences Among Expert Physicians in Areas of Uncertainty in Venous Thromboembolism Management: Results from a Multiple-Choice Questionnaire. [PDF]

J Clin Med
Di Minno A, Spadarella G, Calcaterra IL, Tufano A, Monaco A, Mondello Malvestiti FMP, Tremoli E, Prisco D.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Fondaparinux Sodium

Drugs, 2002
Fondaparinux (Org-31540 / SR-90107A) is a new drug chemically synthesized for treatment and prophylaxis of thromboembolic disease. Fondaparinux is a selective inhibitor of activated factor X. Its structure is the copy of the heparin pentasaccharide sequence, the shortest chain required for antithrombin inhibition of activated factor X without ...
Susan J Keam, Karen L Goa
exaly   +8 more sources

Fondaparinux

Current Pharmaceutical Design, 2005
Fondaparinux is the first drug from the pentassaccharide factor X inhibitor class of anticoagulants to be approved for clinical use. It has been shown to be effective in the prevention of deep vein thrombosis in patients undergoing major orthopaedic surgery of the lower limbs. The drug is also being evaluated for use in the acute coronary syndromes and
Kiat T, Tan, Gregory Y H, Lip
openaire   +3 more sources

Monitoring fondaparinux with the Sonoclot

Blood Coagulation & Fibrinolysis, 2007
Fondaparinux is a new anticoagulant that interacts with antithrombin III and activated coagulation factor X resulting in an inhibition of the coagulation system. It has been successful in doses of 2.5 mg for thromboprophylaxis as well as in higher therapeutic doses of 5-7.5 mg.
Caroline U, Nilsson, Martin, Engström
openaire   +3 more sources

Recombinant Factor VIIa Reverses the in Vitro and Ex Vivo Anticoagulant and Profibrinolytic Effects of Fondaparinux

Journal of Thrombosis and Haemostasis, 2003
Background: Fondaparinux is a synthetic pentasaccharide, which selectively inhibits coagulation factor (F) Xa, and is registered for prevention of venous thromboembolism following hip fracture, hip replacement, and knee replacement surgery.
Ton Lisman, Jcm Meijers
exaly   +2 more sources

Fondaparinux: an overview

Expert Review of Cardiovascular Therapy, 2009
Fondaparinux is a synthetic pentasaccharide belonging to a new group of anticoagulants that inhibit thrombin formation by inhibiting Factor Xa, which is located at the crossing of both the intrinsic and extrinsic pathways. It has a favorable pharmacokinetic profile, and its effect is predictable and the drug does not need platelet monitoring.
Sunil K, Nadar, Deepak, Goyal, Eduard, Shantsila, Pritwish, Banerjee, Gregory Y H, Lip   +4 more
openaire   +2 more sources

Fondaparinux

Drugs & Aging, 2008
Fondaparinux is a synthetic pentasaccharide that inhibits thrombin formation and thrombus development via selective antithrombin mediated inhibition of factor Xa. The complete bioavailability (100%) and elimination half-life of approximately 17 hours allows once-daily administration of fondaparinux.
Singh Sindhu, Peter Silberstein
openaire   +3 more sources